Professional
Added to YB: 2024-05-16
Pitch date: 2024-05-14
NTLA [bullish]
Intellia Therapeutics, Inc.
-53.58%
current return
Author Info
No bio for this author
Company Info
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Market Cap
$2.0B
Pitch Price
$26.65
Price Target
85.00 (+587%)
Dividend
N/A
EV/EBITDA
-4.35
P/E
-3.98
EV/Sales
22.97
Sector
Biotechnology
Category
growth
Intellia Therapeutics, Inc.: Novel Gene Editing Pipeline Advances; Shares Attractive for Long-Term Investors
NTLA: Intellia's gene editing pipeline advances; NTLA-2001 for ATTR P3 tracking ahead, PoS raised to 40%. R&D to stay high as focus on pipeline. Healthy finances w/ $953M cash to '26. Key programs: NTLA-2001 (75% econ), NTLA-3001 (wholly owned). No moat yet given early stage, but +outlook. Price target $85 on blockbuster potential, despite risks. Regeneron deal helps offset costs.
Read full article (10 min)